Original language | English |
---|---|
Pages (from-to) | viii309 |
Number of pages | 1 |
Journal | Annals of Oncology |
Volume | 29 |
Issue number | Supplement 8 |
DOIs | |
Publication status | Published - 1 Oct 2018 |
Event | 43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018 |
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
D. F. McDermott, B. I. Rini, R. J. Motzer, N. M. Tannir, B. Escudier, C. K. Kollmannsberger, H. J. Hammers, C. Porta, S. George, F. Donskov, H. P. Gurney, M.-O. Grimm, M. Harrison, T. E. Hutson, J. Doan, S. Yang, S. Rao, S. Mekan, A. Ambavane, T. Powles
Research output: Contribution to journal › Meeting abstract › peer-review
27
Downloads
(Pure)